The use of systemic corticosteroids in exacerbations of COPD

Chronic obstructive pulmonary disease (COPD) is a progressive, non-reversible, airways disease characterised by long term inflammation that leads to structural deterioration.²

Exacerbations of COPD are acute periods of symptom deterioration where dyspnoea worsens and sputum production increases.

Systemic corticosteroids are the primary tool for managing exacerbations, alongside antibiotics where indicated, and supportive therapy, if in hospital.^1,2

Corticosteroids, when used correctly and well timed, have been shown to reduce hospitalisations and shorten hospital stays.^1,2

Although systemic corticosteroids are very effective for this indication, they are not without risk.

This module will discuss the use of prednisone (brand names: Sone, and Panafcort), prednisolone (brand names: Solone, and Panafcortelone), and hydrocortisone, specifically for the management of COPD exacerbations.¹

National standards

This module primarily relates to the following national standards:

• National Safety and Quality Primary and Community Healthcare Standards: Clinical Governance Standard
• National Safety and Quality Health Service (NSQHS) Standard number 4: Medication Safety.